Roivant Sciences Ltd. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2026 Annual General Meeting of Shareholders held by Roivant Sciences Ltd. on September 16, 2026. The filing details the voting outcomes for three shareholder proposals outlined in the Proxy Statement filed on July 29, 2026.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting results.
Material Changes and Voting Results
A quorum was established with 652,143,869 shares present, representing approximately 90.3% of the 722,406,273 shares entitled to vote. All three proposals were approved:
- Director Election: Shareholders re-elected Daniel Gold and Meghan FitzGerald as Class II directors to serve until the 2029 annual meeting.
- Auditor Ratification: Shareholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending March 31, 2027.
- Executive Compensation: Shareholders approved, on a non-binding advisory basis, the compensation of named executive officers.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document serves as a record of the completed shareholder vote.
Investor Verification Checklist
- Verify the full details of the executive compensation package in the Proxy Statement filed on July 29, 2026.
- Confirm the specific terms of the engagement with Ernst & Young LLP for the 2027 fiscal year.
- Review the biographies and potential conflicts of interest for the re-elected directors, Daniel Gold and Meghan FitzGerald.